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Abstract 
 
Background: Silver-Russell syndrome (SRS) is a clinically and genetically 
heterogeneous condition characterized by severe intrauterine and postnatal growth 
retardation. Loss of DNA methylation at the telomeric imprinting control region 1 (ICR1) 
on 11p15 is an important cause of SRS. 
Methods: We studied the methylation pattern at the H19-IGF2 locus in 201 patients with 
suspected SRS. In an attempt to categorize the patients into different subgroups, we 
developed a simple clinical scoring system with respect to readily and unambiguously 
assessable clinical features. In a second step, the relationship between clinical score and 
epigenetic status was analyzed.  
Results and conclusions: The scoring system emerged as a powerful tool for identifying 
those patients with both a definite SRS phenotype and carrying an epimutation at 11p15. 
53% of the 201 patients initially enrolled fulfilled the criteria for SRS and about 40% of 
them exhibited an epimutation at the H19-IGF2 locus. Methylation defects were 
restricted to patients who fulfilled the diagnostic criteria for SRS. Patients carrying 
epimutations had a more severe phenotype than either the SRS patients with mUPD7 or 
the idiopathic SRS patients. The majority of patients with methylation abnormalities 
showed hypomethylation at both the H19 and IGF2 genes. However, we also identified 
SRS patients where hypomethylation was restricted to either the H19 or the IGF2 gene. 
Interestingly, we detected epimutations in siblings of normal parents, most likely 
reflecting germ cell mosaicism in the fathers. In one family, we identified an epimutation 
in an affected father and his likewise affected daughter.  
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Introduction 
 
Silver-Russell syndrome (SRS, MIM 180860) is a clinically heterogeneous condition 
characterized by severe intrauterine growth retardation, poor postnatal catch up growth, 
craniofacial features such as a triangular shaped face and a broad forehead, body 
asymmetry and a variety of minor malformations. The phenotypic expression changes 
during childhood and adolescence and the facial features and asymmetry usually become 
much more subtle with age. Although different groups have established diagnostic 
criteria for SRS, diagnosis often remains doubtful and children with intrauterine growth 
retardation of various etiologies are spuriously diagnosed with SRS. [1,2] This has caused 
confusion with regard to the true incidence and natural history of SRS.  
It has been recognized since a long time that SRS, which mostly occurs sporadically, is 
very likely a genetically heterogeneous condition with a complex genetic background. [3] 
However, until recently a genetic defect could only be identified in a small subset of 
patients with SRS: maternal UPD7 in about 5-10% of SRS cases and a chromosomal 
rearrangement such as maternal dup(11p15) and dup(7p11.3-p13) or segmental 
mUPD(7q31-qter) in less than 1%. [4,5,6,7,8,9] This situation changed in 2005 when 
hypomethylation of the differentially methylated IGF2/H19 imprinting center region 
(ICR1) at 11p15 was reported in a small number of SRS patients. [10] This finding was 
soon confirmed in larger cohorts of SRS patients and it turned out that partial or complete 
loss of DNA methylation at the telomeric ICR1 on 11p15 represents a major cause for 
SRS. [11,12,13,14] Interestingly, opposite epimutations to the ones observed in SRS 
namely hypermethylation of IGF2/H19 are observed in about 5-10% of patients with the 
Beckwith-Wiedemann syndrome (BWS), an overgrowth syndrome representing in many 
respects the countertype to SRS. [15]   
The 11p15 region comprises two imprinted domains important for the control of fetal and 
postnatal growth, ICR1 and ICR2. ICR1 coordinates the expression of two oppositely 
imprinted genes, H19 and IGF2. H19 encodes a non translated RNA and is expressed 
exclusively from the maternal allele. [16] Hypomethylation of H19 in SRS is proposed to 
lead to biallelic expression of H19, down regulation of IGF2 and hence growth 
restriction. How the 11p15 epimutation causes the specific SRS phenotype is not 
completely understood at the moment. Up to now about 100 patients - mainly children - 
with 11p15 epimutations have been reported in the literature. However, the phenotypic 
spectrum of epimutation carriers and their long term perspective still remain vague. 
The present study aimed at determining more precisely the clinical phenotype(s) 
associated with epimutations at the 11p15 region. We wanted to determine whether the 
patients with methylation defects might comprise a distinct group from idiopathic SRS 
patients and the ones with mUPD7. As a first step we developed a simple clinical scoring 
system with regard to the severity of the SRS phenotype. Then, in a second step, we 
analyzed the relationship between clinical score and epigenetic status.  
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Patients and Methods 
 
Study population (Table 1) 
The study population consisted of 201 individuals with suspected SRS. The patients were 
followed in one of the Genetic Clinics participating in this study (Zürich, Warsaw, 
Minsk, Istanbul) between 1990 and 2007, with the exception of 15 individuals whose 
blood samples were sent to Zürich for genetic analysis. Informed consent for analysis was 
obtained from all individuals included in the study: i.e. adults (patients and parents) and 
parents of underage patients. The study was performed in accordance with national ethics 
guidelines.  
 
Table 1 
Characteristics of study population 
 
  
Patients included 201 
  
Ratio male/female 106/ 95 
  
Patients excluded because of 
other diagnosis, e.g. 
chromosomal aberration, etc. 4 
  
Patients excluded because 
clinical dataset incomplete 29 
  
Sufficient clinical data available 168 
  
Ratio male/female 87/81 
Mean age at evaluation 6.5 y (1-42 y) 
  
 
 
Clinical scoring system (Table 2) 
Each patient was physically examined by a geneticist in one of the participating centers. 
The mean age at physical examination, usually coinciding with the blood sampling, was 
6.5 years, with a range from 1 to 42 years of age. A form with information concerning 
birth measurements, perinatal adaptation, postnatal course, dysmorphic signs, feeding 
behavior, intellectual development and family history was completed by the examining 
physician. Facial features and body asymmetry were assessed from hospital charts or 
childhood photographs in those patients who had already reached adulthood (about 5 % 
of the study sample). The clinical data of all the patients were entered into a database. 
Upon gathering the entire body of clinical information of the cohort we decided to omit 
information on bone age, target height, feeding difficulties, hypoglycemia, sweating and 
teeth abnormalities: although these symptoms represent important diagnostic features in 
SRS, they were often reported imprecisely or were missing. We therefore decided to 
retain in the database only those clinical features of the patients that were readily and 
unambiguously - and therefore reliably - assessable. Using the clinical criteria for SRS 
defined by Price et al. in 1999 as its basis, we established a refined “SRS severity” 
scoring system: Each patient was scored for the five domains, 1. Parameters at birth, 2. 
Postnatal course, 3. Asymmetry, 4. Facial features, 5. Other features (see Table 2). For 
four of the five domains 3 features were scored and 0-3 points were given with 0 
depicting that none of the three features was present, 1 that one was present, etc. 
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Asymmetry was assessed in a different way: Since this is a very important feature in SRS 
but difficult to quantify we decided to score this feature simply as present (3 points) or 
missing (0 points). According to this procedure a minimum total score of 0 points and a 
maximum total score of 15 points was assigned.  
Scoring of all the patients (on the basis of the information collected in the database) was 
performed by one of the authors who was not involved in examination of the patients and 
who was blind with respect to the findings of the molecular analysis. When scoring of the 
cohort was completed, we carefully compared the clinical presentation of those patients 
who displayed scores in the middle range (between 6 to 10 points). It was arbitrarily 
defined that patients with a score ≥ 8 points were classified as SRS patients whereas 
those with lower scores were not (non-SRS patients). 
 
 
Table 2 
Clinical SRS score 
 
    
   
Points 
Parameters at birth 
  
Weight ≤ 10th percentile1   1 
Length ≤ 10th percentile1    1 
Relative macrocephaly2  1 
    
Postnatal course   
No catch up growth; length≤ 3rd percentile3  1 
Normal head circumference; 
OFD ≥3rd and ≤ 97th percentile3 1 
Normal cognitive development4 1 
    
Asymmetry 
   
Face/body/limbs  3 
    
Facial features 
  
Triangular shaped face  1 
High/Bossing forehead  1 
Other: e.g. small chin, thin lips, down turned corners 
of the mouth, late closure of  fontanelle 1 
    
Other features 
  
Clinodactyly 5th finger   1 
Genital abnormalities (e.g. cryptorchidism, 
hypospadias)  1 
Other: e.g. brachymesophalangy, syndactyly toes 
inguinal hernia, pigmentary changes 1 
    
  
Maximal score 15* 
  
  
 
1
 according to [17]  
2
 defined as OFD (occipito frontal diameter) at least 1.5 SD above 
birth weight or length according to [17]  
3
 according to [18] 
4
 defined as attending regular school  
* Patients with scores ≥ 8 were classified as SRS 
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Statistical analysis 
The characteristics of the population were described as percentage for qualitative traits or 
as median, mean and SD for quantitative traits (clinical scoring). The relationship 
between the severity score and the epigenetic status (H19/IGF2 hypomethylation group, 
H19 hypomethylation group, mUPD7 group, idiopathic SRS group) was assessed by one-
way analysis of variance (ANOVA). P values < 0.05 were considered to indicate 
statistical significance. 
 
Methylation analysis for the 11p15 region 
DNA was extracted from peripheral blood samples of all individuals: control individuals, 
patients, and at times parents and siblings. One hundred age-matched healthy individuals 
served as controls. 
The methylation status at H19 and IGF2 was investigated by MLPA (ME030, MRC, 
Holland, version 03, 3-1-2007) according to the protocol supplied by the manufacturer. 
Briefly, approximately 100 ng DNA of each individual were first denatured and 
hybridized overnight with the mixture of probes (supplied with the kit), and then, after 
splitting the sample in two, treated either with ligase alone or with ligase and HhaI. PCR 
reactions were then performed with the reagents and primers supplied in the kit. The PCR 
products were separated by capillary electrophoresis (ABI310). The relative ratio of 
methylation at H19 and IGF2 were calculated as follows: the areas of the peaks of interest 
were divided by the average peak area of the closest control peaks. For each peak, the 
relative area of the sample treated with HhaI was divided by the value obtained for the 
undigested sample. These ratios were normalised by dividing by the average ratios 
obtained for control individuals. Mean values of the 100 control individuals are depicted 
in the legend of Figure 1. The results obtained for the probes 6266-L5772 H19DMR (301 
bp) and 7175-L6784 IGF2 (AY375532.1, 9046-9047) DMR0 (211 bp) were in agreement 
with previous methylation analysis by MSP/DHPLC (data not shown) and were not 
subject to high variability due to the presence of polymorphisms in the target sequences.   
 
Analysis for mUPD7 
The possible occurrence of maternal UPD7 of the two critical regions on chromosome 7 
(7p11.2-p13 and 7q32-34) was investigated prior to this study (data not shown). Analysis 
was performed as described in one of our earlier reports by genotyping DNA samples 
from the patient, mother, and father with 13 chromosome-7-specific polymorphic 
microsatellite markers. [19] At least one and preferably two informative markers per 
region were considered necessary to exclude UPD. 
 
Analysis of familial cases 
In the three families with either two affected siblings or vertical transmission (father and 
daughter affected) we sequenced the CTCF-binding sites in the DMR 5’ of the H19 gene. 
Primer sequences were as reported previously [12]. To document the methylation status at 
another paternally imprinted locus the DMR of the DLK1-GTL2 locus on chromosome 
14q32 was analysed, as described previously. [20] 
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Results 
 
Clinical scoring  
The characteristics of the study population are summarized in Table 1 and 3. According 
to the scoring system described above, 106 individuals had scores of ≥ 8 points and were 
classified as SRS, and this constituted 63% of all the patients scored. A diagnosis of SRS 
was accordingly excluded in 62 individuals (37%). These non-SRS individuals were 
primarily patients with prenatal growth retardation. No definitive diagnosis could be 
established in these patients. 
 
Chromosomal analysis (data not shown)   
One individual with a female phenotype turned out to have a male karyotype in blood 
lymphocytes (46,XY). This patient also carried an epimutation at 11p15 and will be 
reported on in detail in a separate publication. The remainder of the individuals had 
normal karyotypes. 
 
Molecular evaluation  
Epimutations at 11p15 are specific for SRS and are not a cause of nonspecific pre- or 
postnatal growth retardation (Table 3 and 4, Figure 1) 
In 46 patients, hypomethylation at the ICR1 on 11p15 was detected. The clinical data set 
was incomplete in four of these and they were therefore excluded. From the 42 remaining 
patients, 41 had a score of ≥ 8 points and were therefore classified as SRS. From our 
cohort of 200 patients, we could therefore demonstrate that epimutations at 11p15 were 
specific to patients with classical SRS and were not present in patients, primarily 
children, either with isolated growth retardation, body asymmetry or minor anomalies 
similar to those occurring in SRS. There was only one exception to this, a female patient 
in mid-childhood who had a score of 6 and did therefore not fulfill the criteria for SRS. 
This girl actually exhibited a partial hypomethylation specific to H19 (not IGF2). She 
showed borderline prenatal and pronounced postnatal growth retardation, no facial 
dysmorphisms, mild brachyphalangy, and no asymmetry. Unfortunately it was not 
possible to organize a follow up visit for this girl to verify her clinical profile. 
 
Epimutations at 11p15 are restricted to the telomeric gene cluster and are not always 
congruent for the H19 and IGF2 gene (Table 4, Figure 1) 
The MLPA technique applied allowed us to analyze the telomeric and the centromeric 
gene cluster on 11p15 simultaneously. In our cohort no methylation defects were detected 
at the centromeric cluster where CDKN1C and KCNQ1OT1 are located. Differential 
analysis of the H19 and IGF2 genes in the telomeric cluster revealed that the majority of 
patients showed hypomethylation of both H19 and IGF2. Interestingly, 11 patients 
showed selective hypomethylation of H19 and three patients selective hypomethylation 
of IGF2. The IGF2-specific probe showed a broader variation in controls as compared to 
the H19 probe and these results should be interpreted with some reservation, therefore. 
 
Epigenetic- phenotype correlation (Table 4 and Figure 1) 
Patients carrying epimutations had higher scores then the ones with mUPD7 or the 
idiopathic SRS patients, indicating that hypomethylation at 11p15 was associated with a 
severe SRS phenotype. Median severity scores, means and SDs are depicted in Table 4.  
The differences of the severity scores were highly significant when comparing the group 
with combined hypomethylation of H19 and IGF2 with the mUPD7 patients (P<0.001) or 
the idiopathic SRS patients (P<0.001) and still significant when comparing the group 
with hypomethylation of H19 to the mUPD7 and idiopathic SRS group (P<0.01). The 
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scores of the mUPD7 group were not significantly different when compared to the 
idiopathic SRS group (P>0.05). Since we identified only 3 patients with hypomethylation 
restricted to IGF2, no statistical analysis could be performed for this group. 
The methylation index, reflecting the degree of hypomethylation in a given individual, 
seemed to correlate with the score and therefore with clinical severity, at least for H19. 
That is, the relationship between hypomethylation of H19 and clinical severity might be 
quantitative. The small number of patients did not allow statistical analysis with regard to 
this point  
Our scoring system was not designed to establish a correlation between the presence of 
individual features and the epigenotype. However, it was obvious that asymmetry was 
more frequent in those SRS patients with a methylation abnormality when compared to 
the other groups: 65% (27 of 42) of SRS patients with a methylation defect exhibited 
body asymmetry, versus 40% (23 of 58) of idiopathic SRS patients, 20% (2 of 10) of 
patients with mUPD7 and 5% (3 of 62) of non-SRS patients. 
 
Familiar cases with epimutations at 11p15 
Two families, each with two children who displayed hypomethylation of H19 and IGF2, 
were identified. In both families neither of the parents showed clinical signs of SRS and 
methylation analysis in both fathers revealed normal results. In the first family a school-
aged boy and a girl were affected, both of them showing a classical SRS phenotype with 
asymmetry of the limbs in the boy and an asymmetrical face in the girl. In the second 
family the affected siblings were both girls. A report on the second family has already 
been published before epimutations at 11p15 were demonstrated in SRS. [21] Both girls 
were scored at 14 points, reflecting the severe phenotype. In a third family we detected an 
epimutation at 11p15 in both a clinically affected father in his third decade (displaying a 
score of 10) and his affected daughter (score of 12 points). None of the familiar cases 
showed any clinical symptoms in addition to the SRS phenotype. 
Sequence analysis of the CTCF-binding sites in the DMR between the IGF2 and the H19 
genes did not revealed any mutations, and analysis of the paternally imprinted DLK1-
GTL2 locus on chromosome 14q32 showed a normal methylation pattern in the three 
families. 
 
Maternal uniparental disomy (mUPD7) (Table 4and Figure 1) 
Ten individuals displayed maternal uniparental disomy of chromosome 7. Interestingly, 
only 7 out of these 10 individuals fulfilled the diagnostic criteria for SRS according to 
our scoring system. The 7 patients with SRS phenotypes showed significantly lower 
scores when compared to the ones displaying hypomethylation of 11p15. Comparison 
with the idiopathic SRS patients did not show a statistically significant difference of the 
severity scores. 
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Table 3 
Frequency of methylation defects and mUPD7 in the patient cohort 
 
 
 
Patients of 
initial cohort 
 
 
Patients 
clinically scored 
 
 
Patients clinically 
scored as SRS* 
 
# of patients 201 168 106 
  
  
    
Methylation defect  32 29 29  
H19 and IGF2 
   
    
Methylation defect 11 11 10 
H19 
   
    
Methylation defect 3 2 2 
IGF2 
   
    
Total methylation defect 46 (23%) 42 (25%) 41 (38.6%) 
telomeric cluster  
  
    
Methylation defect none none none 
centromeric cluster 
   
    
Maternal UPD7 10 10 7 (6.6%) 
    
No genetic abnormality 
identified 141 116 58 (54.7%) 
    
    
 
*Patients with scores ≥ 8 were classified as SRS.  
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Table 4 
Distribution of clinical severity scores in different groups of patients 
 
Clinical 
Score1 
 
H19 and IGF2 
hypomethylation 
 
H19 
hypomethylation 
 
IGF2 
hypomethylation 
 
 
Maternal 
UPD7  
 
 
Idiopathic 
SRS patients 
 
 
    
 
<8 - 1 - 3 - 
 
    
 
8 - 1 - 3 18 
9 - - - 1 13 
10 4 2 1 1 11 
11 5 2 - 1 8 
12 4 2 1 - 3 
13 6 1 - 1 4 
14 4 2 - - 1 
15 6 - - - - 
 
    
 
Median  score 13 11 - 8 9 
     
 
# of patients 29 patients  11 patients 2 patients 10 patients 58 patients 
     
 
Column2 A B C D E 
     
 
 
1Clinical scores are ranging from 1 (minimal ) to 15 (maximal). Patients with scores ≥ 8 were classified as SRS 
phenotypes, the ones with scores <8 as non SRS phenotypes. 2Columns; Means and SDs: Column A: 12.7±1.7, 
Column B: 11±2.4, Column C: no values due to low number of patients, Column D: 8.6±2.3, Column E:  9.7±1.6.  
P values: Column A vs D: P<0.001, A vs E: P<0.001, B vs D: P<0.01, B vs E: P<0.01, D vs E: P>0.05. Statistical 
significance was considered with a P value <0.05. 
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Figure 1 
Average ratios of methylation at H19 and IGF2 in SRS patients compared to normal 
controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Designation of patient groups (A-E) and number of patients in each group: see Table 4. 
Small symbols: relative methylation at H19 and IGF2 for single patients (one each with 
clinical scores of 6, 8 and 14, respectively). The relative ratios of methylation represent the 
results obtained with the probes: 6266-L5772: H19, and 7175-L6784: IGF2 (MRC-Holland, 
kit ME030 BWS/RSS). Analysis of 100 control individuals revealed a mean value of 1.048 
(SD 0.106) for H19 and 0.99 (SD 0.121) for IGF2. 
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Discussion  
 
This study of 201 individuals with SRS and SRS-like phenotypes confirms the high 
frequency of methylation abnormalities at the H19/IGF2 locus in SRS: epimutations 
occurred in about 40% of patients with SRS. In total, we identified more than 40 
individuals with partial hypomethylation at the ICR1 on 11p15, which is the largest 
cohort of SRS patients with epimutations reported in the literature so far. Methylation 
defects were with one exception restricted to patients who fulfilled the diagnostic criteria 
for SRS.   
Establishing the diagnosis of SRS is not always easy and there is no general consensus 
for diagnostic criteria. This has added confusion to the question of frequency of 11p15 
epimutations in SRS: While the French group which was first to describe methylation 
abnormalities on 11p15 in SRS detected epimutations in 64% of a large series of SRS 
patients, other groups identified this abnormality in their cohorts at lower frequencies of 
30-40%.[summarized in 22] Differences in detection rates might be explained to some 
extent by the molecular techniques used: it was recently shown that MLPA is more 
sensitive than Southern blot analysis for assessment of the methylation status at 11p15. 
[23] Much more important, however, are the criteria used for establishing the SRS 
diagnosis in a given individual. The frequency of 40% epimutation carriers in our cohort 
therefore reflects the fact that we included patients with a broad clinical spectrum from 
borderline to classical SRS phenotypes.  
To address the question of clinical heterogeneity and stringency of diagnostic criteria in 
SRS we developed a very simple scoring system which permits calculating a SRS 
severity score ranging from 0-15 points. The advantage of this scoring system is that it 
allows the determination of the phenotype on a quantitative basis. It emerged that patients 
with hypomethylation had significantly higher scores and therefore more severe 
phenotypes when compared to the idiopathic SRS patients where no genetic abnormality 
was identified or the patients with mUPD7: 95% of the patients with a methylation 
abnormality had scores between 10 and 15 points, whereas only 46% of the idiopathic 
SRS patient were within this range. This has important implication for the diagnostic 
strategy in an individual with SRS: The chance of detecting a methylation abnormality in 
a child with SRS and a low score of 8 or 9 points is very small and analysis for mUPD7 
would be recommended first. On the contrary, methylation analysis should be the first 
diagnostic step in those patients with high scores between 10 and 15 points, especially in 
individuals with asymmetry. One might speculate that the milder phenotype of the SRS 
patients in whom we could not identify a genetic abnormality might carry a methylation 
abnormality on 11p15 which escaped analysis in blood samples. It is well known from 
BWS that methylation defects at the11p15 locus mostly occur as somatic mosaics and 
that the detection rate depends on the tissue analyzed. It would be interesting, therefore, 
to test other tissues as for example fibroblasts for methylation abnormalities in those 
“blood negative” patients. 
IGF2 is a paternally expressed fetal growth factor and H19 a maternally expressed non-
coding RNA for which the function is still not very well understood. Imprinted 
expression of these two genes is regulated by the action of the H19 DMR. It largely 
remains unknown how biallelic silencing of IGF2 and activation of H19 translates into 
the specific SRS phenotype. It has been shown that hypomethylation of H19 in SRS 
patients is associated with decreased levels of IGF2 mRNA in fibroblasts, but IGF2 
serum levels seem to be mostly normal in epimutation carriers. [10, 13, 24]. This 
observation is not surprising given the development- and tissue-dependent expression 
pattern of this growth factor, with monoallelic expression from the paternal allele in fetal 
life and biallelic expression in postnatal life. [25].  
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We observed selective hypomethylation for either H19 or IGF2 in 13 patients, indicating 
that hypomethylation of IGF2 alone seems to be sufficient to cause classical SRS. The 
phenotype of those patients with selective hypomethylation at one locus was generally 
milder than in the patients displaying hypomethylation of H19 and IGF2. However, given 
the small number of patients (11 for selective H19 and 2 for IGF2 demethylation) this 
observation needs to be confirmed. To date there is limited knowledge on the methylation 
status of IGF2 in SRS and it is not know to what extent the proposed silencing 
contributes to the SRS phenotype. A recent paper on methylation changes at the 
IGF2/H19 locus in SRS, BWS and Wilm’s tumor, reports on similar methylation 
abnormalities at H19 and IGF2 in the congenital growth disorders, but different 
methylation profiles in tumors. [26] The authors propose different mechanisms of 
imprinting loss in neoplastic cells and growth disorders. Along these lines it remains open 
whether loss of imprinting in those SRS patients with combined H19/IGF2 
hypomethylation is caused by a different mechanism than in the cases with selective 
hypomethylation of H19 or IGF2. 
In this study we describe for the first time familial cases of hypomethylation at the 11p15 
locus. This finding has important implications for both genetic counseling and 
determination of the origin of the epimutations. The setting of epigenetic marks in germ 
cells has been studied in detail in mouse and to a lesser extend also in humans. [27] 
Methylation marks at imprinted loci are thought to be erased in primordial germ cells and 
then reacquired during spermatogenesis and oogenesis. In the majority of epimutation 
carriers identified in this study the loss of the paternal methylation mark may have 
resulted from a deficient acquisition of methylation during spermatogenesis or from lack 
of maintenance of the methylation mark on the paternal allele after fertilization. The two 
families for whom we identified epimutations in siblings most likely represent germ cell 
mosaicism of an incorrect methylation mark at the ICR1 during spermatogenesis in the 
fathers.  
The third family where the epimutation was transmitted from an affected father to his 
daughter is the first case of vertical transmission through the male germ line described in 
the literature. The underlying mechanism is difficult to explain in this family. Obviously 
the affected father displays a missing methylation mark at the H19/IGF2 DMD in 
somatic and germ cells. Reprogramming of the methylation pattern in his primordial 
germ cells did not lead to a correction (setting of a methylation mark) but the “mistake” 
was continued when resetting of the methylation pattern at imprinted loci occurred during 
spermatogenesis. How this mistake was “memorized” in the germ cells of the father 
remains to be explained. Father and daughter showed a classical SRS phenotype and did 
not have additional symptoms indicative of a different etiology compared to the sporadic 
cases. Both displayed partial hypomethylation at the H19/IGF2 DMD and analysis of 
another paternally imprinted locus at 14q (DLK1-GTL2) showed a normal methylation 
pattern. Therefore, although the clinical picture and the molecular findings do not point 
into this direction it can not be excluded that father and daughter carry a mutation in one 
of the DNA methyl-transferase genes or an other gene involved in DNA-methylation. 
It is interesting to note that the 4 children of the two families with suspected germ cell 
mosaicism in the fathers displayed hemihypoplasia. It has been hypothesized that 
asymmetry in BWS and SRS is caused by mosaic distribution of post-zygotically 
acquired epimutations. [28] However, the observation of asymmetry in the offspring of 
men with suspected germ cell mosaicism for epimutataions at the H19/IGF2 locus 
renders it rather unlikely that asymmetry can be explained by mosaic distribution of the 
epimutation: In those children the epimutation did most likely not emerge post-
zygotically and the asymmetry has therefore to be explained by another still unknown 
mechanism. 
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In summary, our study has important implication for diagnosis and genetic counseling in 
SRS. First, the clinical scoring system we developed is a simple but powerful tool to 
direct the diagnostic efforts rapidly towards methylation analysis in those patients with a 
severity score in the upper range. Second, we demonstrate that hypomethylation of H19 
or IGF2 alone appears to be sufficient to cause SRS. Third and most importantly, the 
observation of germ cell mosaicism and vertical transmission from an affected father to 
his child demonstrate that there is a recurrence risk for epimutations in SRS. 
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